This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bou, G.
Right arrow Articles by Martínez-Beltrán, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bou, G.
Right arrow Articles by Martínez-Beltrán, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2000, p. 428-432, Vol. 44, No. 2
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Cloning, Nucleotide Sequencing, and Analysis of the Gene Encoding an AmpC beta -Lactamase in Acinetobacter baumannii

Germán Bou* and Jesús Martínez-Beltrán

Servicio de Microbiología, Hospital Ramón y Cajal, 28034 Madrid, Spain

Received 13 January 1999/Returned for modification 29 August 1999/Accepted 5 November 1999


    ABSTRACT
Top
Abstract
Text
References

A clinical strain of Acinetobacter baumannii (strain Ab RYC 52763/97) that was isolated during an outbreak in our hospital and that was resistant to all beta -lactam antibiotics tested produced three beta -lactamases: a TEM-1-type (pI, 5.4) plasmid-mediated beta -lactamase, a chromosomally mediated OXA-derived (pI, 9.0) beta -lactamase, and a presumptive chromosomal cephalosporinase (pI, 9.4). The nucleotide sequence of the chromosomal cephalosporinase gene shows for the first time the gene encoding an AmpC beta -lactamase in A. baumannii. In addition, we report here the biochemical properties of this A. baumannii AmpC beta -lactamase.


    TEXT
Top
Abstract
Text
References

Acinetobacter spp. are recognized as important opportunist pathogens mainly in immunocompromised patients (9, 10). Their contribution to nosocomial infection has increased over the past three decades (6, 7, 27), and several outbreaks of hospital infection have been reported worldwide (5; G. Bou, G. Cerveró, D. Malpica, M. Pérez-Vázquez, L. De Rafael, and J. Martínez-Beltrán, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. K-120, 1998). Though prevalent in nature (4) and generally regarded as commensals of human skin and of the human respiratory tract (1, 15), they have been implicated as the cause of serious infectious diseases such as pneumonia, urinary tract infection, endocarditis, wound infection, meningitis, and septicemia, involving mostly patients with impaired host defenses (6, 9, 30). Antimicrobial treatment of serious infections due to Acinetobacter, particularly those caused by Acinetobacter baumannii, is complicated by the widespread multidrug resistance pattern of the organism (8, 18). With respect to beta -lactam antibiotics, the most common mechanism of resistance is due to the synthesis of beta -lactamases encoded either by the chromosome or by plasmids (9). So far, several class A and class D plasmid-encoded beta -lactamases conferring different phenotypes of resistance to A. baumannii have been described (9, 24, 31, 32; G. Bou, A. Oliver, and J. Martínez-Beltrán, submitted for publication). Likewise, different chromosomally mediated cephalosporinases (pI, >8) have also been reported (9, 25), and sometimes these cephalosporinases have been particularly difficult to visualize by isoelectric focusing (24). In any case, nucleotide sequencing of the ampC gene has never been described. The main objective of this work was to clone and sequence the gene encoding the chromosomally mediated AmpC beta -lactamase from a multiresistant A. baumannii clinical strain (Ab RYC 52763/97) isolated during an outbreak at our hospital in 1997 (Bou et al., 38th ICAAC). A detailed description of its biochemical characteristics is also provided.

The susceptibility testing of the Ab RYC 52763/97 strain was performed by an agar dilution method, as recommended by the National Committee for Clinical Laboratory Standards (23), using Mueller-Hinton agar and an inoculum size of 104 CFU per spot. Antibiotics were kindly provided as powders of a fixed potency by their corresponding manufacturers. The antibiotic susceptibility profiles of all strains included in this study are shown in Table 1. The strain Ab RYC 52763/97 was highly resistant to all beta -lactam antibiotics tested, with minimum inhibitory concentrations (MICs) of imipenem and meropenem being 128 and 256 µg/ml, respectively.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   MICS of beta -lactams

beta -Lactamases were analyzed by isoelectric focusing as described by Matthew et al. (22). The sonicated extract of strain Ab RYC 52763/97 contained three beta -lactamases, as follows: one yielded a band with a pI of 5.4 and was cloned after amplification with bla-TEM primers C1 (5'-GGGAATTCTCGGGGAAATGTGCGCGGAAC) and C2 (5'-GGGATCCGAGTAAACTTGGTCTGACAG) (TEM-1 type); a second focused at a pI of 9.0, and after cloning (clone pBMB-1), the gene nucleotide sequence showed homology with those of OXA-derived beta -lactamases (Bou et al., submitted); and the third focused at a pI of 9.4 and likely corresponded to a chromosomal cephalosporinase. With the A. baumannii clinical strain no transfer of resistance phenotype was observed in conjugation experiments. By alkaline lysis (28), a plasmid of 22 kb was isolated in this strain. By enzymatic restriction and ligation techniques (28) only a TEM-1 gene was found in this plasmid.

Chromosomal DNA of Ab RYC 52763/97 was prepared by the method of Grimont and Grimont (16), digested with HindIII (Boehringer-Mannheim, Mannheim, Germany), and ligated into the HindIII site of pBGS18- (29). Recombinant plasmids were introduced into Escherichia coli TG1 by transformation with CaCl2 (28), and transformants were selected on Luria-Bertani agar plates supplemented with ampicillin (25 µg/ml) and kanamycin (50 µg/ml). Three E. coli transformants were obtained on selective medium supplemented with the antibiotics mentioned above. They harbored a recombinant plasmid, designated pGER1, with an insert of about 2.2 kb.

The beta -lactam susceptibility pattern of the three transformants was identical, displaying resistance to ampicillin, cefazolin, cefuroxime, and, to a lesser extent, ceftazidime, while the susceptibility to the remaining beta -lactams tested was differently affected by the presence of the recombinant plasmid pGER1 (Table 1). The MICs of ticarcillin, cefotaxime, cefepime, and aztreonam for E. coli TG1(pGER1) were increased, whereas the MICs of cefoxitin, imipenem, and meropenem remained unchanged. Regarding the effect of the beta -lactamase inhibitors sulbactam and tazobactam, the MICs of ampicillin, cefotaxime, and ceftazidime decreased by 4- to 16-fold, in contrast with the very slight effect obtained with clavulanic acid. By isoelectric focusing, the single band of beta -lactamase activity in the E. coli transformant cofocused with the beta -lactamase (pI, 9.4) of the wild-type strain (results not shown).

In order to perform the sequencing reactions the 2.2-kb insert from the plasmid pGER1 was cloned in the pUC18 multicopy plasmid (29), resulting in the plasmid pGER2. Sequencing was carried out with the Taq DyeDeoxiTerminator Cycle Sequencing Kit and with primers specific to the coding sequence, and the sequence was analyzed in an automatic DNA sequencer (377 Abi-Prims; Perkin-Elmer). The entire sequence of the fragment was determined twice for accuracy.

The sequenced fragment was 2,195 bp long and contained only one open reading frame (ORF) (Fig. 1). An ATG codon initiated an 1,152-bp ORF which ended with a TAA codon (383 amino acids long). The initiation codon was preceded by a Shine-Dalgarno ribosome-binding sequence, AGGAG. GenBank database searches with this ORF revealed similarities with several class C chromosomal and plasmid-mediated beta -lactamases (Table 2). The highest identity (40.5 to 42.3%) was observed with the following beta -lactamases: AmpC of Aeromonas sobria, CMY-1, AmpC of Serratia marcescens, FOX-2, FOX-3, and AmpC of Pseudomonas aeruginosa; 35 to 40% identity was seen for AmpC beta -lactamases from E. coli, Proteus stuartii, Yersinia enterocolitica, Morganella morganii, Enterobacter cloacae, and Citrobacter freundii. The deduced peptide sequence contained conserved motifs found in serine beta -lactamases (14), as follows: the SXSK motif of the active site of AmpC, the class C typical motif YXN, and the KTG domain. The nucleotide sequence of the flanking regions of the ampC gene (about 400 bp on each side) did not show inverted repeated sequences suggestive of the presence of a transposable element. This ampC gene was probably not inserted in an integron, since the 59-base element (specific to gene cassettes inserted in integron structures) was not observed on the flanking regions.


View larger version (55K):
[in this window]
[in a new window]
  		FIG. 1.   Nucleotide sequence of the ampC gene. The deduced amino acid sequence of AmpC beta -lactamase is shown below the nucleotide triplets. The boldface ATG and TAA represent the initiation and termination codons, respectively. A putative Shine-Dalgarno (S.D.) ribosomal recognition site (underlined) is indicated. The positions of the primers used to sequence the gene are indicated by underlining with arrowheads. The beta -lactamase active site S-V-S-K, the conserved triad K-T-G, and the class C typical motif Y-X-N are presented in boldface. A putative terminator sequence is underlined.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   Percent identity of amino acid sequences of A. baumannii AmpC and other class C beta -lactamases

The synthesis of chromosomal AmpC beta -lactamases in some gram-negative rods such as E. cloacae, C. freundii, and P. aeruginosa may be inducible and involves genes such as the repressor ampR and ampD. The first is located immediately upstream from the ampC gene and is divergently transcribed (19). Sequencing of the flanking regions of the gene encoding the AmpC beta -lactamase produced by the Ab RYC 52763/97 strain did not show homology with the ampR regulatory gene. Induction experiments with cefoxitin (one-half of the MIC) performed with the E. coli transformant carrying the ampC gene and with the original Ab RYC 52763/97 strain did not show an increase in the synthesis of the AmpC beta -lactamase, determined as specific enzymatic activity, when the inducer was added (data not shown). These experiments indicated that the A. baumannii AmpC beta -lactamase in this strain is noninducible.

The substrate profile of the AmpC beta -lactamase was determined with the enzyme partially purified by G-75 Sephadex (Pharmacia Fine Chemicals AB, Uppsala, Sweden). Initial hydrolysis rates were monitored spectrophotometrically (UVIKON-930) at 25°C in 0.05 M phosphate buffer (pH 7.4), as described previously (12). The Vmax values indicate that cephaloridine is hydrolyzed more quickly than ampicillin and that cefoxitin and imipenem are not hydrolyzed at detectable levels (Table 3). Inhibition studies showed that the remaining beta -lactamase activities in the presence of 100 µM each inhibitor were as follows: clavulanic acid, 91%; sulbactam, 40%; and tazobactam, 45%. The 50% inhibitory concentrations (IC50s) were obtained from semilogarithmic plots of enzymatic activity against inhibitor concentration. The IC50s were 270 µM for clavulanic acid, 7 µM for sulbactam, and 8 µM for tazobactam. These results correlated with the decrease in the MICs of ampicillin, cefotaxime, and ceftazidime in combination with these inhibitors against E. coli TG1 harboring AmpC beta -lactamase (pGER1).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 3.   Kinetic and inhibition parameters of the A. baumannii AmpC beta -lactamasea

In order to detect the ampC gene in different A. baumannii isolates, a PCR assay was performed. Six genotypically different A. baumannii strains (REP-PCR tested) with different antibiotic susceptibility patterns that had been collected in our hospital during the previous five years were used. The reactions were carried out with a 50-µl volume of a reaction mixture containing 20 mM Tris-HCl (pH 8.8), 100 mM potassium chloride, 2.0 mM magnesium chloride, 200 µM deoxynucleotide triphosphate, 50 pmol of each primer, 500 ng of the chromosomal DNA, and 2.5 U of Taq polymerase (Roche). The primers of the ampC coding region, P1 (5'-TAAACACCACATATGTTCCG) and P2 (5'-ACTTACTTCAACTCGCGACG), were used. Amplification reactions were submitted to the following program: initial denaturation (4 min at 94°C) followed by 30 cycles of denaturation (1 min at 94°C), annealing (1 min at 50°C), and extension (2 min at 72°C), with a single extension of 10 min at 72°C. The amplified 663-bp product was resolved by electrophoresis in a 1.5% (wt/vol) agarose gel containing ethidium bromide (50 µg/ml). As shown in Fig. 2, the ampC gene was extensively spread between the six A. baumannii isolates but not in Acinetobacter junii. This result strongly suggests that the AmpC beta -lactamase may play a role in the beta -lactam resistance of A. baumannii.


View larger version (38K):
[in this window]
[in a new window]
  		FIG. 2.   Detection of the ampC gene in different A. baumannii isolates. The amplified products were resolved by 1.5% agarose gel electrophoresis and stained with ethidium bromide (50 µg/ml). Lanes 1 and 11, DNA molecular weight markers III and V, respectively (Boehringer-Mannheim); lane 2, negative control (genomic DNA of Listeria monocytogenes amplified with primers P1 and P2); lanes 3 to 8, A. baumannii strains (Ab 1 to 6); lane 9, A. junii strain; lane 10, positive control (strain Ab RYC 52763/97).

The presence of chromosomal beta -lactamases in the genus Acinetobacter was first suggested by Matthew and Harris (21). By examining beta -lactamases from 30 strains of Acinetobacter, Joly-Guillou et al. (17) revealed a cephalosporinase with a pI of >8.0 in all these strains. Afterwards, Blechschmidt et al. (11) reported the purification and biochemical characterization of an extracellular beta -lactamase with a pI of 9.3 produced by Acinetobacter calcoaceticus. Other attempts have been carried out in order to characterize the A. baumannii cephalosporinase biochemically (25), but nothing has been reported about the gene encoding the enzyme. The present study describes the genetic and biochemical characteristics of the A. baumannii AmpC beta -lactamase. The following important features are noteworthy. (i) The amino acid sequence is closely related to the class C cephalosporinases, and the highest similarity was obtained with the A. sobria AmpC beta -lactamase. (ii) The enzyme shows a typical cephalosporinase substrate profile (13). (iii) Enzymatic inhibition assays and antibiotic susceptibility studies showed a moderate inhibitory effect of sulbactam and tazobactam against A. baumannii AmpC beta -lactamase. As for clavulanic acid, only a very slight inhibitory effect was observed. (iv) No AmpC beta -lactamase induction was observed when cefoxitin was added, and no ampR sequences were found on the flanking regions of the ampC gene. Nevertheless, whether a regulatory AmpR-like protein gene exists in A. baumannii, although not adjacent to the ampC gene, remains to be elucidated.

Certainly, resistance to beta -lactam antibiotics in A. baumannii is a multifactorial problem involving resistance mechanisms in addition to beta -lactamases (9); thus, in our study, the beta -lactam MICs conferred by the AmpC beta -lactamase, even by means of a multicopy plasmid carried by E. coli TG1, did not reach the high MICs observed for the Ab RYC 52763/97 clinical strain (MICs conferred by the OXA-derived beta -lactamase [Bou et al., submitted] are not relevant when compared with the A. baumannii clinical strain). Note also that the MICs of the carbapenems were not affected by the presence of the AmpC beta -lactamase even in a multicopy plasmid. Nevertheless, the presence of the ampC gene in all six different A. baumannii strains tested suggests that the AmpC beta -lactamase, in combination with other beta -lactam resistance mechanisms, may play an important role in beta -lactam resistance in A. baumannii.

In summary, we report here for the first time the cloning, sequencing, and analysis of the ampC gene and the biochemical characterization of the AmpC beta -lactamase from an A. baumannii clinical strain.

Nucleotide sequence accession number. The nucleotide sequence of the ampC gene has been given the EMBL database accession no. AJ009979.


    ACKNOWLEDGMENTS

We thank L. de Rafael for his critical reading.


    FOOTNOTES

* Corresponding author. Present address: Department of Immunology and Division of Infectious Diseases, Mayo Clinic, 200 First St. SW, Guggenheim 516, Rochester, MN 55905. Phone: (507) 284-9504. Fax: (507) 284-3757. E-mail: germanbou{at}mailcity.com.


    REFERENCES
Top
Abstract
Text
References

1. Al-Khoja, M. S., and J. H. Darrell. 1979. The skin as the source of Acinetobacter and Moraxella species occurring in blood cultures. J. Clin. Pathol. 32:497-499[Abstract/Free Full Text].
2. Bauernfeind, A., I. Stemplinger, R. Jungwirth, R. Wilhem, and Y. Chong. 1996. Comparative characterization of the cephamycinase blaCMY-1 gene and its relationship with other beta -lactamase genes. Antimicrob. Agents Chemother. 40:1926-1930[Abstract].
3. Bauernfeind, A., S. Wagner, R. Jungwirth, J. Schneider, and D. Meyer. 1997. A novel class C beta -lactamase (FOX-2) in Escherichia coli conferring resistance to cephamycins. Antimicrob. Agents Chemother. 41:2041-2046[Abstract].
4. Baumann, P. 1968. Isolation of Acinetobacter from soil and water. J. Bacteriol. 96:39-42[Abstract/Free Full Text].
5. Bergogne-Bérézin, E. 1995. The increasing significance of outbreaks of Acinetobacter spp.: the need for control and new agents. J. Hosp. Infect. 30:441-452.
6. Bergogne-Bérézin, E., M. L. Joly-Guillou, and J. F. Vieu. 1987. Epidemiology of nosocomial infections due to Acinetobacter calcoaceticus. J. Hosp. Infect. 10:105-113[CrossRef][Medline].
7. Bergogne-Bérézin, E., and M. L. Joly-Guillou. 1985. An underestimated nosocomial pathogen, Acinetobacter calcoaceticus. J. Antimicrob. Chemother. 16:535-538[Free Full Text].
8. Bergogne-Bérézin, E., and M. L. Joly-Guillou. 1986. Comparative activity of imipenem, ceftazidime and cefotaxime against Acinetobacter calcoaceticus. J. Antimicrob. Chemother. 18(Suppl. E):35-39[Abstract/Free Full Text].
9. Bergogne-Bérézin, E., and K. J. Towner. 1996. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9:148-165[Medline].
10. Bergogne-Bérézin, E., M. L. Joly-Guillou, and K. J. Towner. 1996. History and importance of Acinetobacter spp.: role in infections, treatment and cost implications, p. 1-12. In E. Bergogne-Bérézin, et al. (ed.), Acinetobacter: microbiology, epidemiology, infections, management. CRC Press, Boca Raton, Fla.
11. Blechschmidt, B., P. Borneleit, and H. P. Kleber. 1992. Purification and characterization of an extracellular beta -lactamase produced by Acinetobacter calcoaceticus. J. Gen. Microbiol. 138:1197-1202[Abstract/Free Full Text].
12. Bou, G., J. Martínez-Beltrán, G. Cerveró, and J. C. Pérez-Díaz. 1999. Biochemical and genetic characteristics of TEM-29B, a novel extended spectrum beta -lactamase. FEMS Microbiol. Lett. 174:185-190[Medline].
13. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for beta -lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233[Medline].
14. Ghuysen, J. M. 1991. Serine beta -lactamases and penicillin-binding proteins. Annu. Rev. Microbiol. 45:37-67[CrossRef][Medline].
15. Glew, R. H., R. C. Moellering, and L. J. Kunz. 1977. Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine 56:79-97[Medline].
16. Grimont, F., and P. A. D. Grimont. 1986. Ribosomal nucleic acid gene restriction patterns as potential taxonomic tools. Ann. Inst. Pasteur Microbiol. 137B:165-175[CrossRef].
17. Joly-Guillou, M. L., E. Bergogne-Bérézin, and N. Moreau. 1987. Enzymatic resistance to beta -lactams and aminoglycosides in Acinetobacter calcoaceticus. J. Antimicrob. Chemother. 20:773-775[Free Full Text].
18. Joly-Guillou, M. L., E. Bergogne-Bérézin, and J. F. Vieu. 1990. Epidemiologie et résistance aux antibiotiques des Acinetobacter en milieu hospitalier. Presse Med. 19:357-361.
19. Lodge, J. M., S. D. Minchin, L. Piddock, and J. W. Busby. 1990. Cloning, sequencing and analysis of the structural gene and regulatory region of the Pseudomonas aeruginosa chromosomal ampC beta -lactamase. Biochem. J. 272:627-631[Medline].
20. Marchese, A., G. Arlet, G. C. Schito, P. H. Lagrange, and A. Philippon. 1998. Characterization of FOX-3, an AmpC-type plasmid-mediated beta -lactamase from an Italian isolate of Klebsiella oxytoca. Antimicrob. Agents Chemother. 42:464-467[Abstract/Free Full Text].
21. Matthew, M., and A. M. Harris. 1976. Identification of beta -lactamase by analytical isoelectric focusing: correlation with bacterial taxonomy. J. Gen. Microbiol. 94:55-67[Abstract/Free Full Text].
22. Matthew, M., A. M. Harris, M. J. Marshall, and G. W. Ross. 1975. The use of analytical isoelectric focusing for detection and identification of beta -lactamases. J. Gen. Microbiol. 88:169-178[Medline].
23. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. Paton, R., R. S. Miles, J. Hood, and S. G. B. Amyes. 1993. ARI 1: beta -lactamase-mediated imipenem resistance in Acinetobacter baumannii. Int. J. Antimicrob. Agents 2:81-88.
25. Perilli, M., A. Felici, A. Oratore, G. Cornaglia, G. Bofiglio, G. M. Rossolini, and G. Amicosante. 1996. Characterization of the chromosomal cephalosporinase produced by Acinetobacter lwoffii and Acinetobacter baumannii clinical isolates. Antimicrob. Agents Chemother. 40:715-719[Abstract].
26. Rasmussen, B. A., D. Keeney, Y. Yang, and K. Bush. 1994. Cloning and expression of a cloxacillin-hydrolyzing enzyme and a cephalosporinase from Aeromonas sobria AER 14M in Escherichia coli: requirement for an E. coli chromosomal mutation for efficient expression of the class D enzyme. Antimicrob. Agents Chemother. 38:2078-2085[Abstract/Free Full Text].
27. Retailliau, H. F., A. W. Hightower, R. E. Dixon, and J. R. Allen. 1979. Acinetobacter calcoaceticus: a nosocomial pathogen with an unusual seasonal pattern. J. Infect. Dis. 139:371-375[Medline].
28. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
29. Spratt, B. G., P. J. Hedge, T. S. Heesen, A. Edelman, and J. K. Broome-Smith. 1986. Kanamycin-resistant vectors that are analogues of plasmids pUC8, pUC9, pEMBL8, and pEMBL9. Gene 41:337-342[CrossRef][Medline].
30. Tilley, P. A. G., and F. J. Roberts. 1994. Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical settings. Clin. Infect. Dis. 18:896-900[Medline].
31. Vahaboglu, H., R. Öztürk, G. Aygün, F. Coskunkan, A. Yaman, A. Kaygusuz, H. Leblebicioglu, I. Balik, K. Aydin, and M. Otkun. 1997. Widespread detection of PER-1-type extended-spectrum beta -lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob. Agents Chemother. 41:2265-2269[Abstract].
32. Vila, J., M. Navia, J. Ruiz, and C. Casals. 1997. Cloning and nucleotide sequence analysis of a gene encoding an OXA-derived beta -lactamase in Acinetobacter baumannii. Antimicrob. Agents Chemother. 41:2757-2759[Abstract].

Antimicrobial Agents and Chemotherapy, February 2000, p. 428-432, Vol. 44, No. 2
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Beceiro, A., Lopez-Rojas, R., Dominguez-Herrera, J., Docobo-Perez, F., Bou, G., Pachon, J., the Spanish Network for Research in Infectious Dis, (2009). In Vitro Activity and In Vivo Efficacy of Clavulanic Acid against Acinetobacter baumannii. Antimicrob. Agents Chemother. 53: 4298-4304 [Abstract] [Full Text]  
  • Beceiro, A., Perez, A., Fernandez-Cuenca, F., Martinez-Martinez, L., Pascual, A., Vila, J., Rodriguez-Bano, J., Cisneros, J. M., Pachon, J., Bou, G., and the Spanish Group for Nosocomial Infection (GE, (2009). Genetic Variability among ampC Genes from Acinetobacter Genomic Species 3. Antimicrob. Agents Chemother. 53: 1177-1184 [Abstract] [Full Text]  
  • Jacoby, G. A. (2009). AmpC {beta}-Lactamases. Clin. Microbiol. Rev. 22: 161-182 [Abstract] [Full Text]  
  • Nemec, A., Krizova, L., Maixnerova, M., Diancourt, L., van der Reijden, T. J. K., Brisse, S., van den Broek, P., Dijkshoorn, L. (2008). Emergence of carbapenem resistance in Acinetobacter baumannii in the Czech Republic is associated with the spread of multidrug-resistant strains of European clone II. J Antimicrob Chemother 62: 484-489 [Abstract] [Full Text]  
  • Bratu, S., Landman, D., Martin, D. A., Georgescu, C., Quale, J. (2008). Correlation of Antimicrobial Resistance with {beta}-Lactamases, the OmpA-Like Porin, and Efflux Pumps in Clinical Isolates of Acinetobacter baumannii Endemic to New York City. Antimicrob. Agents Chemother. 52: 2999-3005 [Abstract] [Full Text]  
  • Peleg, A. Y., Seifert, H., Paterson, D. L. (2008). Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin. Microbiol. Rev. 21: 538-582 [Abstract] [Full Text]  
  • Beceiro, A., Fernandez-Cuenca, F., Ribera, A., Martinez-Martinez, L., Pascual, A., Vila, J., Rodriguez-Bano, J., Cisneros, J. M., Pachon, J., Bou, G., on behalf of the Spanish Group for Nosocomial Infe, (2008). False extended-spectrum {beta}-lactamase detection in Acinetobacter spp. due to intrinsic susceptibility to clavulanic acid. J Antimicrob Chemother 61: 301-308 [Abstract] [Full Text]  
  • Beceiro, A., Perez-Llarena, F. J., Perez, A., Tomas, M. d. M., Fernandez, A., Mallo, S., Villanueva, R., Bou, G. (2007). Molecular characterization of the gene encoding a new AmpC {beta}-lactamase in Acinetobacter baylyi. J Antimicrob Chemother 59: 996-1000 [Abstract] [Full Text]  
  • Siroy, A., Molle, V., Lemaitre-Guillier, C., Vallenet, D., Pestel-Caron, M., Cozzone, A. J., Jouenne, T., De, E. (2005). Channel Formation by CarO, the Carbapenem Resistance-Associated Outer Membrane Protein of Acinetobacter baumannii. Antimicrob. Agents Chemother. 49: 4876-4883 [Abstract] [Full Text]  
  • Tomas, M. d. M., Beceiro, A., Perez, A., Velasco, D., Moure, R., Villanueva, R., Martinez-Beltran, J., Bou, G. (2005). Cloning and Functional Analysis of the Gene Encoding the 33- to 36-Kilodalton Outer Membrane Protein Associated with Carbapenem Resistance in Acinetobacter baumannii. Antimicrob. Agents Chemother. 49: 5172-5175 [Abstract] [Full Text]  
  • Heritier, C., Poirel, L., Lambert, T., Nordmann, P. (2005). Contribution of Acquired Carbapenem-Hydrolyzing Oxacillinases to Carbapenem Resistance in Acinetobacter baumannii. Antimicrob. Agents Chemother. 49: 3198-3202 [Abstract] [Full Text]  
  • Hujer, K. M., Hamza, N. S., Hujer, A. M., Perez, F., Helfand, M. S., Bethel, C. R., Thomson, J. M., Anderson, V. E., Barlow, M., Rice, L. B., Tenover, F. C., Bonomo, R. A. (2005). Identification of a New Allelic Variant of the Acinetobacter baumannii Cephalosporinase, ADC-7 {beta}-Lactamase: Defining a Unique Family of Class C Enzymes. Antimicrob. Agents Chemother. 49: 2941-2948 [Abstract] [Full Text]  
  • Poirel, L., Marque, S., Heritier, C., Segonds, C., Chabanon, G., Nordmann, P. (2005). OXA-58, a Novel Class D {beta}-Lactamase Involved in Resistance to Carbapenems in Acinetobacter baumannii. Antimicrob. Agents Chemother. 49: 202-208 [Abstract] [Full Text]  
  • Nagano, N., Nagano, Y., Cordevant, C., Shibata, N., Arakawa, Y. (2004). Nosocomial Transmission of CTX-M-2 {beta}-Lactamase-Producing Acinetobacter baumannii in a Neurosurgery Ward. J. Clin. Microbiol. 42: 3978-3984 [Abstract] [Full Text]  
  • Beceiro, A., Dominguez, L., Ribera, A., Vila, J., Molina, F., Villanueva, R., Eiros, J. M., Bou, G. (2004). Molecular Characterization of the Gene Encoding a New AmpC {beta}-Lactamase in a Clinical Strain of Acinetobacter Genomic Species 3. Antimicrob. Agents Chemother. 48: 1374-1378 [Abstract] [Full Text]  
  • Ribera, A., Fernandez-Cuenca, F., Beceiro, A., Bou, G., Martinez-Martinez, L., Pascual, A., Cisneros, J. M., Rodriguez-Bano, J., Pachon, J., Vila, J. (2004). Antimicrobial Susceptibility and Mechanisms of Resistance to Quinolones and {beta}-Lactams in Acinetobacter Genospecies 3. Antimicrob. Agents Chemother. 48: 1430-1432 [Abstract] [Full Text]  
  • Segal, H., Nelson, E. C., Elisha, B. G. (2004). Genetic Environment and Transcription of ampC in an Acinetobacter baumannii Clinical Isolate. Antimicrob. Agents Chemother. 48: 612-614 [Abstract] [Full Text]  
  • Corvec, S., Caroff, N., Espaze, E., Giraudeau, C., Drugeon, H., Reynaud, A. (2003). AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J Antimicrob Chemother 52: 629-635 [Abstract] [Full Text]  
  • Mammeri, H., Poirel, L., Mangeney, N., Nordmann, P. (2003). Chromosomal Integration of a Cephalosporinase Gene from Acinetobacter baumannii into Oligella urethralis as a Source of Acquired Resistance to {beta}-Lactams. Antimicrob. Agents Chemother. 47: 1536-1542 [Abstract] [Full Text]  
  • Fernandez-Cuenca, F., Martinez-Martinez, L., Conejo, M{a} C., Ayala, J. A., Perea, E. J., Pascual, A. (2003). Relationship between {beta}-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 51: 565-574 [Abstract] [Full Text]  
  • Manchanda, V., Singh, N. P. (2003). Occurrence and detection of AmpC {beta}-lactamases among Gram-negative clinical isolates using a modified three-dimensional test at Guru Tegh Bahadur Hospital, Delhi, India. J Antimicrob Chemother 51: 415-418 [Abstract] [Full Text]  
  • Heritier, C., Poirel, L., Aubert, D., Nordmann, P. (2003). Genetic and Functional Analysis of the Chromosome-Encoded Carbapenem-Hydrolyzing Oxacillinase OXA-40 of Acinetobacter baumannii. Antimicrob. Agents Chemother. 47: 268-273 [Abstract] [Full Text]  
  • Danes, C., Navia, M. M., Ruiz, J., Marco, F., Jurado, A., Jimenez de Anta, M. T., Vila, J. (2002). Distribution of {beta}-lactamases in Acinetobacter baumannii clinical isolates and the effect of Syn 2190 (AmpC inhibitor) on the MICs of different {beta}-lactam antibiotics. J Antimicrob Chemother 50: 261-264 [Abstract] [Full Text]  
  • Zhang, Z., Yu, Y., Musser, J. M., Palzkill, T. (2001). Amino Acid Sequence Determinants of Extended Spectrum Cephalosporin Hydrolysis by the Class C P99 beta -Lactamase. J. Biol. Chem. 276: 46568-46574 [Abstract] [Full Text]  
  • Bou, G., Oliver, A., Ojeda, M., Monzón, C., Martínez-Beltrán, J. (2000). Molecular Characterization of FOX-4, a New AmpC-Type Plasmid-Mediated beta -Lactamase from an Escherichia coli Strain Isolated in Spain. Antimicrob. Agents Chemother. 44: 2549-2553 [Abstract] [Full Text]  
  • Bou, G., Cerveró, G., Domínguez, M. A., Quereda, C., Martínez-Beltrán, J. (2000). Characterization of a Nosocomial Outbreak Caused by a Multiresistant Acinetobacter baumannii Strain with a Carbapenem-Hydrolyzing Enzyme: High-Level Carbapenem Resistance in A. baumannii Is Not Due Solely to the Presence of beta -Lactamases. J. Clin. Microbiol. 38: 3299-3305 [Abstract] [Full Text]  
  • Bou, G., Oliver, A., Martínez-Beltrán, J. (2000). OXA-24, a Novel Class D beta -Lactamase with Carbapenemase Activity in an Acinetobacter baumannii Clinical Strain. Antimicrob. Agents Chemother. 44: 1556-1561 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bou, G.
Right arrow Articles by Martínez-Beltrán, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bou, G.
Right arrow Articles by Martínez-Beltrán, J.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»